Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “equal weight” rating restated by Barclays in a research note issued on Monday. They currently have a GBX 780 ($13.08) price objective on the stock. Barclays’ target price indicates a potential downside of 25.43% from the stock’s previous close.

Shares of Smith & Nephew plc (LON:SN) opened at 1036.00 on Monday. Smith & Nephew plc has a 1-year low of GBX 720.00 and a 1-year high of GBX 1120.00. The stock has a 50-day moving average of GBX 919.2 and a 200-day moving average of GBX 891.9. The company’s market cap is £9.251 billion.

A number of other analysts have also recently weighed in on SN. Analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,000 ($16.76) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Thursday. They now have a GBX 1,125 ($18.86) price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Tuesday, May 20th. They now have a GBX 1,065 ($17.85) price target on the stock. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of GBX 934.31 ($15.66).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.